News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC
Jan 17, 2025, 17:53

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared on X:

“Intermittent or Continuous FOLFIRI + PANITUMUMAB RAS and BRAF Wild-Type Metastatic CRC: The IMPROVE Trial

Intermittent FOLFIRI + pani has similar outcomes in terms of PFSot and OS compared to continuous Rx. Detrimental effect in Right sided tumors.”

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Clinical Oncology

Authors: Antonio Avallone, Francesco Giuliani, Alfonso De Stefano, Giuseppe Santabarbara, Guglielmo Nasti, Vincenzo Montesarchio, Gerardo Rosati, Antonino Cassata, Silvana Leo, Carmela Romano, Emiliano Tamburini, Lucrezia Silvestro, Claudio Lotesoriere, Anna Nappi, Daniele Santini, Antonella Petrillo, Alfredo Colombo, Antonio Febbraro, Alessandra Leone, Francesco Mannavola, Maria Maddalena Laterza, Francesco Izzo, Alberto Sobrero, Paolo Delrio, Diana Giannarelli, and Alfredo Budillon.

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

 

Akhil Santhosh Alberto Sobrero Alessandra Leone Alfonso De Stefano Alfredo Budillon Alfredo Colombo Anna Nappi Antonella Petrillo Antonino Cassata Antonio Avallone Antonio Febbraro cancer Carmela Romano Claudio Lotesoriere Daniele Santini Diana Giannarelli Emiliano Tamburini Francesco Giuliani Francesco Izzo Francesco Mannavola Gerardo Rosati Giuseppe Santabarbara Guglielmo Nasti Lucrezia Silvestro Maria Maddalena Laterza OncoDaily Oncology Paolo Delrio Silvana Leo Vincenzo Montesarchio
Special Coverage
Opinion
Apr 19, 2025, 01:47
Essential Medicines for Children with Cancer: From Access to Action – A Powerful OncoDaily Virtual Forum
Opinion
Apr 19, 2025, 01:45
Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book
Blog
Apr 19, 2025, 01:45
Shray Saheba: I had the exciting opportunity to present my research at the National Research Conference hosted by Brown University
Blog
Apr 19, 2025, 01:42
Highlights from Brown University's Inaugural National Undergraduate Research Conference
Blog
Apr 19, 2025, 01:22
National Cancer Control Plans ensures better prevention, early diagnosis and treatment for all - UICC
Blog
Apr 19, 2025, 01:19
Milos Grujic: Patient-Reported Outcomes with Talazoparib plus Enzalutamide
Science
Apr 19, 2025, 01:13
Filipe Nadir Caparica Santos: The potential of internationally trained physicians
Blog
Apr 19, 2025, 01:05
Join ESTRO 2025 for a series of debate sessions on radiation oncology
Blog
Apr 19, 2025, 01:00
Norman Ng: Joanne Chiu discusses the remarkable advancements in cancer treatment and the potential for long-term survival
Blog
Apr 19, 2025, 00:20
Heba ElNokoudy: Comprehensive patient counseling significantly reduces adverse drug events
Blog
Apr 18, 2025, 20:22
Applications are open for the ESMO Research Fellowship
Blog
Apr 18, 2025, 20:12
Caitríona Duggan: Delighted for the opportunity to share our work at MASCC